

Development of inflammatory cell-targeting exosome-based therapeutics for Ophthalmology via **** inhibition

OPHTHALMOLOGY	Lead
Product Type	Exosome-based therapeutics
Indication	Confidential
Target	Undisclosed signaling pathway
MoA(Mechanism of Action)	<ol style="list-style-type: none"> 1) Targeted intracellular delivery of protein inhibitor for cellular signaling 2) Dose-Dependent reduction in the expression of pro-inflammatory cytokines and chemokines and subsequent infiltration of neutrophil and monocytes
Competitiveness	<ol style="list-style-type: none"> 1) Inhibition of disease progression by direct suppression of immune cell activity 2) Selective effects on inflammatory responses 3) Biocompatible and safe profiles
Development Stage	Lead
Route of Administration	Confidential